Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol
AssigneeHormos Nutraceutical Oy Ltd.
InventorMarja Mutanen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for decreasing the intracellular, especially nuclear level of β-catenin in an individual and to a method for the prevention or treatment of a disease or condition in an individual, wherein said disease or condition is related to a mutant APC gene or to an elevated level of intracellular β-catenin. Furthermore, the invention relates to methods for screening a subject to determine if said subject is a carrier of a mutant APC gene, and to methods for diagnosing an individual's predisposition for a disease or condition in an individual, said disease or condition being related to a mutant APC gene or to an elevated level of intracellular β-catenin.
Claims2
A method for treating an individual having Familial Adenomatous Polyposis (FAP), comprising administering to said individual an effective amount of hydroxymatairesinol wherein the intracellular level of β-catenin protein in said individual is decreased.
A method for treatment of a disease or condition in an individual, said disease or condition being related to a mutant APC (adenomatous polyposis coli) gene, or to an elevated level of intracellular β-catenin, said method comprising administering to said individual an effective amount of hydroxymatairesinol wherein said disease or condition is FAP.
Dependencies are inferred from the claim text.